The genetic landscape of glioma is characterized by alterations in genes encoding epidermal growth factor receptor (EGFR), phosphate and tensin homolog deleted on chromosome 10 (PTEN), neurofibromatosis 1 (NF1), RAS, TP53, and cyclin dependent kinase inhibitor 2 (CDKN2A/B), among others, leading to cell proliferation and tumorigenesis [3,4]. The gene discussed is NF1; the disease is central nervous system cancer.